RxDoctor Payments Data

Amanda Whitaker

Primary Care · Mountain Home, ARNPI 1295235331

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $328 of the $422 with a category attached, or 77.7%. 13 manufacturers reported payments, led by Astellas Pharma US Inc at 34.8% of the total. Reporting peaked in 2023 at $192 and has fallen 74.1% since, to $50 in 2025.

$422in general payments, 2019–2025

Across 19 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$147
  • Johnson & Johnson$64
  • Novo Nordisk$34
  • Myriad Women's Health, Inc.$30
  • Currax Pharmaceuticals LLC$24
  • AbbVie$20
  • plus $103 from 7 others

What the payments were for

  • Food & beverage$32878%
  • Education$9422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$422 in reported general payments places this provider in the 60th percentile of 76 primary care providers in Arkansas.

See all primary care providers in Arkansas

Medicare billing

Part B allowed, 2024
$16,872
Medicare patients
66
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$12,154
MounjaroTirzepatide11$11,118
MyrbetriqMirabegron15$9,239
Estradiol21$1,526
Albuterol Sulfate HfaAlbuterol Sulfate20$1,095
Omeprazole40$487
Bupropion XlBupropion Hcl15$382
Losartan Potassium34$353
Levothyroxine Sodium69$344
Metoprolol Tartrate32$229
Lisinopril40$183
Fluticasone Propionate14$173
Escitalopram Oxalate21$171
Pravastatin Sodium38$167
Pioglitazone Hcl12$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$12,15413 claims
Lilly USA, LLCMounjaro$14$11,11811 claims
Astellas Pharma US IncMyrbetriq$147$9,23915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 76 primary care providers in Arkansas.

Other primary care in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →